Discontinue Januvia (Sitagliptin)
When adding Ozempic (semaglutide) to a patient currently on Farxiga (dapagliflozin) and Januvia (sitagliptin), discontinue Januvia. Both Januvia and Ozempic work through incretin-based mechanisms, making their combination redundant and offering no additional benefit, while Farxiga provides complementary cardiovascular and renal protection that should be maintained.
Rationale for This Decision
Why Keep Farxiga and Stop Januvia
The 2025 ADA Standards of Care clearly establish the therapeutic hierarchy for diabetes medications 1. GLP-1 receptor agonists like semaglutide demonstrate superior efficacy compared to DPP-4 inhibitors like sitagliptin across all key outcomes:
- Glucose-lowering efficacy: Semaglutide is classified as "high to very high" while sitagliptin is only "intermediate" 1
- Weight loss: Semaglutide produces "intermediate to very high" weight loss; sitagliptin is weight-neutral 1
- Cardiovascular benefits: Semaglutide shows proven MACE reduction; sitagliptin is neutral 1
- Renal protection: Semaglutide benefits albuminuria outcomes; sitagliptin is neutral 1
The Mechanistic Overlap Problem
Both semaglutide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) work through the incretin system. Sitagliptin prevents the breakdown of endogenous GLP-1, while semaglutide directly activates GLP-1 receptors with far greater potency. Using both simultaneously provides no additive benefit - the powerful exogenous GLP-1 receptor activation from semaglutide completely overshadows any incremental GLP-1 preservation from sitagliptin.
Research directly comparing these agents confirms semaglutide's superiority: In head-to-head trials, semaglutide reduced HbA1c by 1.9-2.2% versus only 0.7% with sitagliptin, with significantly greater weight loss 2.
Why Farxiga Must Stay
Dapagliflozin (Farxiga) operates through a completely different, insulin-independent mechanism - inhibiting renal glucose reabsorption via SGLT2 1. This provides:
- Complementary glucose control through a distinct pathway
- Proven cardiovascular benefits including heart failure reduction 1
- Renal protection that continues even when glucose-lowering effects diminish at lower eGFR 1
- Synergistic effects with GLP-1 agonists: Multiple studies demonstrate the combination of dapagliflozin plus semaglutide produces superior outcomes compared to either alone, with HbA1c reductions of 1.2-2.2% 3, 4
Recent 2024-2025 trials specifically examining triple therapy (dapagliflozin + sitagliptin + metformin) versus dual therapy consistently show that adding dapagliflozin to existing therapy provides significant additional benefit, while the DPP-4 inhibitor contributes minimally 5, 6.
Practical Implementation
Stop Januvia immediately when starting Ozempic - no tapering is required for DPP-4 inhibitors 7. Continue Farxiga at the current dose without interruption.
Expected Outcomes After the Switch
- Greater HbA1c reduction (expect an additional 1.0-1.5% decrease beyond current control)
- Weight loss of 2-4 kg over 6 months
- Improved cardiovascular risk profile
- Maintained renal protection from the SGLT2 inhibitor
Critical Safety Considerations
Monitor for hypoglycemia risk if the patient is also on insulin or sulfonylureas - these may need dose reduction when adding semaglutide 7. The combination of dapagliflozin and semaglutide does not increase hypoglycemia risk when used without insulin secretagogues 1.
Counsel about GI side effects from semaglutide (nausea, vomiting, diarrhea) - these are typically mild-to-moderate and transient, improving after the first 4-8 weeks 8. Advise smaller meal portions and slower eating to mitigate symptoms.
Continue SGLT2 inhibitor sick-day precautions: Temporarily hold Farxiga during acute illness, dehydration, or before surgery 1.
Common Pitfall to Avoid
Do not make the mistake of stopping Farxiga instead of Januvia. Some clinicians incorrectly assume they should keep the DPP-4 inhibitor because it's "safer" or has fewer GI side effects. This sacrifices proven cardiovascular and renal benefits for inferior glucose control. The evidence unequivocally supports the dapagliflozin + semaglutide combination over sitagliptin + semaglutide 3, 4, 5, 6.
No Pharmacokinetic Interactions
Dapagliflozin has no pharmacokinetic interactions with either sitagliptin or semaglutide, so the transition is pharmacologically straightforward 9.